Grants and Contributions

About this information

In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.

The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.

Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.

Found 48736 records

$361,400.00

Dec 1, 2021

Individual or sole proprietorship

Agreement:

Op. Gr.:Emerging COVID-19 Res. Gaps & Priorities - HIV and SARS-CoV-2

Agreement Number:

163306

Duration: from Dec 1, 2021 to Nov 30, 2022
Description:

Accelerate the availability and use of high-quality and real-time evidence and/or solutions to support Canada’s ongoing response to the pandemic in order to better prevent, detect, treat and manage COVID-19; AND
b. Generate evidence related to one or more marginalized population(s), including for instance: Black and other communities marginalized by race; First Nations, Inuit, Métis and Urban Indigenous Peoples; communities historically excluded from research; those experiencing health inequity; persons with disabilities and individuals across diverse health status (e.g. high risk populations, individuals with comorbid conditions); those experiencing gendered impacts of the pandemic; and those in life stages that have been underrepresented in research (e.g. pregnant people, children, older adults).

Organization: Canadian Institutes of Health Research
Program Name: Research in Priority Areas
Location: Winnipeg, Manitoba, CA R3T 2N2

$500,000.00

Dec 1, 2021

Individual or sole proprietorship

Agreement:

Op. Gr.:Emerging COVID-19 Res. Gaps & Priorities - HIV and SARS-CoV-2

Agreement Number:

163305

Duration: from Dec 1, 2021 to Nov 30, 2022
Description:

Accelerate the availability and use of high-quality and real-time evidence and/or solutions to support Canada’s ongoing response to the pandemic in order to better prevent, detect, treat and manage COVID-19; AND
b. Generate evidence related to one or more marginalized population(s), including for instance: Black and other communities marginalized by race; First Nations, Inuit, Métis and Urban Indigenous Peoples; communities historically excluded from research; those experiencing health inequity; persons with disabilities and individuals across diverse health status (e.g. high risk populations, individuals with comorbid conditions); those experiencing gendered impacts of the pandemic; and those in life stages that have been underrepresented in research (e.g. pregnant people, children, older adults).

Organization: Canadian Institutes of Health Research
Program Name: Research in Priority Areas
Location: Montreal, Quebec, CA H3G 1A4

$286,800.00

Dec 1, 2021

Individual or sole proprietorship

Agreement:

Op. Gr.:Emerging COVID-19 Res. Gaps & Priorities - HIV and SARS-CoV-2

Agreement Number:

163308

Duration: from Dec 1, 2021 to Nov 30, 2022
Description:

Accelerate the availability and use of high-quality and real-time evidence and/or solutions to support Canada’s ongoing response to the pandemic in order to better prevent, detect, treat and manage COVID-19; AND
b. Generate evidence related to one or more marginalized population(s), including for instance: Black and other communities marginalized by race; First Nations, Inuit, Métis and Urban Indigenous Peoples; communities historically excluded from research; those experiencing health inequity; persons with disabilities and individuals across diverse health status (e.g. high risk populations, individuals with comorbid conditions); those experiencing gendered impacts of the pandemic; and those in life stages that have been underrepresented in research (e.g. pregnant people, children, older adults).

Organization: Canadian Institutes of Health Research
Program Name: Research in Priority Areas
Location: St. John's, Newfoundland & Labrador, CA A1C 5S7

$7,000,000.00

Feb 1, 2023

For-profit organization

Agreement:

LAU-7b as next-generation COVID-19 therapeutic - COVID-19 Response-Stage 3 (TI): antiviral & Inflammation Controlling Therapeutic Drug Clinical Evaluation

Agreement Number:

1002706

Duration: from Feb 1, 2023 to Mar 31, 2025
Description:

The project is focusing on Phase 3 pivotal study of LAU-7b in moderate-to-severe hospitalized COVID-19 patients, and has a component allowing the transition to a new Phase 2 clinical development in mild-to-moderate non-hospitalized COVID-19 patients.

LAU-7b is a next-generation COVID-19 antiviral that addresses the gap between early infection and critical COVID-19 disease, and aims for broad applicability at-home or in hospital. Because its host-directed mechanism, LAU-7b has the potential to work on all mutations of COVID-19, and other coronaviruses. Results from the Phase 2 pilot study showed 100% reduction in the risk of progression to mechanical ventilation and death in hospitalized moderate-to-severe patient.

Organization: National Research Council Canada
Program Name: Industrial Research Assistance Program – Contributions to Firms
Location: Montreal, Quebec, CA H3A 2R7

$1,783,815.00

Jun 1, 2024

For-profit organization

Agreement:

H5N1 -mRNA vaccine for Highly Pathogenic Avian Influenza for Protection of Canadian Livestock

Agreement Number:

1028947

Duration: from Jun 1, 2024 to Mar 4, 2026
Description:

Providence Therapeutics will initiate work to design and develop an mRNA vaccine drug candidate for a relevant strain using their mRNA and INTENT lipid nanoparticle (LNP) platforms.

Organization: National Research Council Canada
Program Name: Industrial Research Assistance Program – Contributions to Firms
Location: Calgary, Alberta, CA T2J 3J1

$16,615.00

May 12, 2020

Not-for-profit organization or charity

Agreement:

Contribution to Mazaya Organization

Agreement Number:

16087

Duration: from May 12, 2020 to Apr 30, 2021
Description:

Supporting Jabra Hospital Intensive Care Unit for Sudan's Response to COVID19 through the Provision of Medical Supplies

Organization: Global Affairs Canada
Program Name: Canada Fund for Local Initiatives
Location: Bahri, SD

$220,674.00

Jun 26, 2020

Not-for-profit organization or charity

Agreement:

Contribution to CAUSE Canada

Agreement Number:

16023

Duration: from Jun 26, 2020 to Apr 30, 2021
Description:

Preventing and responding to COVID-19 through community mobilization in the Koinadugu and Falaba Districts of Sierra Leone

Organization: Global Affairs Canada
Program Name: Canada Fund for Local Initiatives
Location: Calgary, Alberta, CA T2N 2A1

$100,000.00

Jun 11, 2020

Not-for-profit organization or charity

Agreement:

Contribution to World Vision Eswatini

Agreement Number:

16110

Duration: from Jun 11, 2020 to Apr 30, 2021
Description:

Reduce the spread and impact of COVID-19 on children in Eswatini through increased awareness and service provision.

Organization: Global Affairs Canada
Program Name: Canada Fund for Local Initiatives
Location: Mbabane, SZ

Not-for-profit organization or charity

Agreement:

Contribution to Radio Moçambique (Radio Mozambique)

Agreement Number:

16113

Duration: from Jun 8, 2020 to Apr 30, 2021
Description:

Strenghtening informal street-vendors and public transport passenger's capacity to respond to COVID-19 through provision of information.

Organization: Global Affairs Canada
Program Name: Canada Fund for Local Initiatives
Location: Maputo, MZ

Not-for-profit organization or charity

Agreement:

Contribution to Católicas por el derecho a decidir, A.C.

Agreement Number:

16115

Duration: from Jun 16, 2020 to Apr 30, 2021
Description:

Promoting assistance for victims of gender-based violence in the context of the COVID-19 emergency in Mexico

Organization: Global Affairs Canada
Program Name: Canada Fund for Local Initiatives
Location: Mexico, MX